Clinical Trials Logo

Schistosoma Haematobium clinical trials

View clinical trials related to Schistosoma Haematobium.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03893097 Completed - Schistosoma Mansoni Clinical Trials

Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children

SchistoSAM
Start date: October 14, 2019
Phase: Phase 3
Study type: Interventional

The SchistoSAM study is an open label, two-arm, individually-randomized controlled trial with a non-inferiority design, conducted in northern Senegal. The study aims at determining if the efficacy of one and of repeated courses of artesunate-mefloquine (AM) is respectively similar to or higher than that of a standard praziquantel (PZQ) treatment. Secondly, the study will assess if novel DNA- and antigen-based diagnostics are more accurate than microscopy in assessing antischistosomal treatment response.

NCT ID: NCT01163877 Completed - Malaria, Falciparum Clinical Trials

Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma

Start date: April 2010
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the change in iron metabolism in relation to malaria and helminth infections using a stable isotope technique.

NCT ID: NCT00870649 Completed - Clinical trials for Schistosoma Haematobium

Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium

Bilhvax3
Start date: February 2009
Phase: Phase 3
Study type: Interventional

Objectives:To reduce the risk of S. haematobium pathology recurrences during the three years following vaccine administration and to control the safety of this therapeutic strategy in children exposed to urinary schistosomiasis. Methodology : Phase III trial, self-contained, randomized, double blind, in two parallel groups receiving 3 injections at D0, W4, W8 and a boost at W52, one group receiving "Bilhvax", the other one placebo, in S. haematobium infected children pretreated by two doses of PZQ (at W9 and W8) Patient included : Infected school children, 6 to 9 years of age. Primary objective : To demonstrate a significant delay of recurrence of the schistosomiasis pathology in vaccine group compared to control group in the 3 years period following the first administration (between D0 and W152). Secondary objective : safety Duration : February 2009 to March 2012

NCT ID: NCT00713999 Completed - Clinical trials for Sexually Transmitted Infections

Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar

FGS/MGS/STI
Start date: August 2001
Phase: N/A
Study type: Interventional

A cross-sectional study of urogenital schistosomiasis and sexually transmitted infections (STI) prevalence and associated morbidity in a rural community in Madagascar. Clearance of infections and resolution of morbidity were subsequently studied in two phases following systematic anti-STI and anti-schistosoma treatment, respectively.

NCT ID: NCT00510159 Completed - Clinical trials for Schistosoma Haematobium

Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis

Start date: August 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of praziquantel versus As+SMP (Co-Arinate FDC ®) in the treatment of Schistosoma haematobium in 6-15 year old Malian children. The nul-hypothesis in this study is that the combination of As+SMP is more effective than praziquantel in the treatment of S. haematobium infected children.